
Serina Therapeutics and AgeX Therapeutics Announce Merger Agreement
Key Highlights
- The merger will combine Serina's expertise in polymer therapeutics with AgeX's focus on aging and regeneration therapeutics.
- The combined company will continue to advance its pipeline of polymer therapeutics and AgeX's cell and drug-based therapeutic candidates for various diseases.
- Both CEOs emphasize the merger's potential to provide additional resources and expand their therapeutic pipelines.
Source: Business Wire
Notable Quotes
“ This merger with AgeX provides Serina with a public platform to advance our polymer therapeutics platform and continue the development of our lead programs, ”
- Randall Moreadith, M.D., Ph.D., CEO of Serina Therapeutics.
“ The merger with Serina is expected to provide AgeX with additional resources to advance our current product candidates and expand our therapeutic pipeline, ”
- Michael D. West, Ph.D., CEO of AgeX Therapeutics
SoH's Take
- The merger between Serina Therapeutics and AgeX Therapeutics represents a strategic move to combine expertise in polymer therapeutics and aging therapeutics, potentially leading to innovative treatments for various diseases.
- With the combined resources and platforms, the merged entity is poised to accelerate the development of their respective pipelines, offering potential growth opportunities in the biopharmaceutical sector.